Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

Roche and Monte Rosa enter molecular glue degrader partnership worth over $2bn

The companies will work on therapies for targets in cancer and neurological diseases

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

Roche presents positive results for spinal muscular atrophy treatment Evrysdi in babies

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

EU flag

EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer

More than 550,000 people are diagnosed with breast cancer each year in Europe

- PMLiVE

ICR study finds way to determine efficacy of experimental breast cancer drugs

The findings could speed up the development of targeted therapies for breast cancer

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links